Derived from cancellous bone, OsteoSponge provides a natural scaffold for cellular ingrowth and exposes bone-growth-inducing proteins to the healing environment. The malleable properties of OsteoSponge enable it to fill and conform to irregular bony defects. Due to its shape memory characteristics, OsteoSponge will expand to completely fill a void after graft placement. The unique mechanical and biological properties make OsteoSponge an ideal bone graft for use with spinal fusion devices, in arthrodesis, or in fracture sites. *See handling characteristics in video to left.

Key Differentiators

• Patented processing ensures inductive potential 
• Patented product ensures clinical efficacy
• Unique compressible and deformable handling characteristics
• Validated sterilization  

• 100% human demineralized cancellous bone
• Interconnected porosity
• Osteoinductive potential
• Compressible handling characteristics
• Press fit surgical technique
• Radiolucent to allow for accurate follow-up
• Sterility assurance level (SAL) 10^-6
• 5 year shelf life
• Room-temperature storage

May be used in a number of orthopedic, reconstructive, and dental applications. It can be used in bone grafting procedures in combination with autologous bone or other forms of allograft bone, or it can be used by itself as a bone graft in non-weight bearing applications. The technology is two-fold; it allows for allografts comprised of human bone to become compressible, while maintaining the spectrum of native growth factors inherent to bone. More specifically:

• U.S. Patent No. 8,574,825 protects the processing methods for OsteoSponge allografts. During manufacture the physical characteristics of each graft is assessed. The demineralization process is stopped when the graft exhibits the desired compressible handling. By stopping the demineralization process as soon as possible we minimize exposure to the harsh acidic conditions of the demineralization phase of processing.  This patented process leads to the next patent. 
• U.S. Patent No. 8,992,964 provides patented coverage of the OsteoSponge allografts themselves, specifically to the optimal preservation of bone morphogenetic protein-2 (BMP-2). This optimal growth factor preservation is due to the patented demineralization process covered in the first patent.